---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-107442"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-10-07T13:23:58+00:00"
generated_at: "2026-10-12T15:57:22.734766+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize value

## Summary
- Cadrenal authorized a formal strategic process to evaluate licensing/sale of assets, partnerships, or business combinations; no timetable or assurance of a transaction.
- Cadrenal engaged Tungsten Advisors as exclusive strategic financial advisor and cited strong interest from potential strategic partners.
- Pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000; CAD-1005 gained FDA alignment on a Phase 3 pathway for heparin-induced thrombocytopenia.
- CAD-1005 has FDA Orphan Drug and Fast Track designations and EMA orphan drug status; tecarfarin is Phase 3-ready; frunexian is a Factor XIa inhibitor.
- CEO Quang X. Pham said the pipeline has reached clinical and regulatory maturity, citing FDA alignment on CAD-1005's Phase 3 development pathway.

## SEC filing metadata
- accession: 0001213900-26-107442
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-10-07T13:23:58+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/0001213900-26-107442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/ea0307947-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-107442
- JSON: https://secwatch.observer/filing/0001213900-26-107442.json
- Plain text: https://secwatch.observer/filing/0001213900-26-107442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.